Tim Smith

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.

In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.

These data on patients in Japan demonstrate positive efficacy and safety findings in real-world settings, with uniquely positive results among bio-naïve patients.

In this analysis, links between psoriasis and metabolic and cardiovascular risk were evaluated along with correlations between biomarkers and severity.

These findings result from a systematic review and meta-analysis looking at the utilization of dupilumab among children and adolescents with atopic dermatitis.

These data point to the role of environmental factors in the development of atopic dermatitis and indicate targeted prevention strategies for those known to be impacted.

In this analysis, the investigators evaluated the temporal increase in hair shedding amounts following topical minoxidil utilization.

This analysis highlights the increased risk among those with psoriasis for developing such ocular conditions as conjunctivitis, dry eye, and conjunctival hyperemia.

Caution may be needed when prescribing 5 mg of oral minoxidil to patients with alopecia and pericardial risk factors such as systemic lupus erythematosus.

These data highlight the comparability of Humira, the adalimumab originator, to the drug’s biosimilars in terms of efficacy in treating psoriasis.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

These data highlight the long-term maintenance of bimekizumab responses among individuals with psoriasis, looking at bio-naïve and bio-switched patients.

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Baricitinib treatment was safe among patients with alopecia areata over 48 weeks in a real-world treatment setting.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

Investigators highlight systemic treatments for psoriatic disease that maintain lower rates of serious infections among older adults suffering from psoriatic disease.

These recent data demonstrate small doses of doxycycline, an anti-inflammatory medication, may help manage lymphocytic scarring alopecia.

This March 2025 SOCS News Update highlights misconceptions related to skin health, the value of diversity in clinical research, and SOCS Symposium highlights.

These data highlight the potential benefit of continuous treatment with subcutaneous spesolimab for generalized pustular psoriasis (GPP).

These pivotal phase 3 data on povorcitinib were the results of the STOP-HS clinical trial, with results suggesting both efficacy and safety for hidradenitis suppurativa.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.

A panel discussion at the Skin of Color Society Scientific Symposium features 3 notable speakers highlighting dermatology residency questions and more.

In these survey findings, a variety of notable findings regarding perceptions of awareness of CHE as well as views on available drugs are highlighted.

This quiz, the third in a series of 4, tests one's knowledge on prevention and treatment of actinic keratosis based on the 2021 AAD guidelines.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

This Month in Review summary highlights various news highlights featured in February’s dermatology news coverage.

In this episode, Victoria Barbosa, MD, MPH, MBA, and Janiene Luke, MD, highlight insights and misconceptions about alopecia.